Market Overview

Emergent BioSolutions Announces Data from Phase IIb Trial for MVA85A Published in The Lancet

Data were published in The Lancet today from a Phase IIb clinical
trial evaluating the safety and efficacy of MVA85A in preventing
tuberculosis (TB) in infants. MVA85A is a TB vaccine candidate designed
to boost immune responses already primed by the Bacille Calmette-Guérin
(BCG) vaccine, the currently licensed and widely used TB vaccine.

Data show that a single dose of MVA85A is not sufficient to confer
statistically significant protection against TB disease or infection in
infants who had been vaccinated at birth with BCG. There were 32 cases
of TB disease in the infants that received BCG + MVA85A compared with 39
cases of disease among those receiving BCG + placebo. Non-significant
vaccine efficacy was measured at 17.3% (95% CI -31.9% to

See full press release

Posted-In: News Guidance Contracts Management Global

 

Related Articles (EBS)

Around the Web, We're Loving...

Get Benzinga's Newsletters